By Devika Patel
Knoxville, Tenn., Jan. 13 - Rosetta Genomics Ltd. said it arranged a $5.06 million registered direct offering of units.
The company will sell 2.53 million units of one common share and a half-share warrant at $2.00 apiece.
The whole warrants are exercisable at $2.50 for five years.
Rodman & Renshaw, LLC is the agent.
Settlement is expected on Jan. 19.
Proceeds will be used for general corporate purposes.
The Rehovot, Israel, biopharmaceutical company develops microRNA-based therapeutic and diagnostic agents with a focus on cancer and infectious diseases.
| Issuer: | Rosetta Genomics Ltd.
|
| Issue: | Units of one common share and a half-share warrant
|
| Amount: | $5.06 million
|
| Units: | 2.53 million
|
| Price: | $2.00
|
| Warrants: | One half-share warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $2.50
|
| Agents: | Rodman & Renshaw, LLC
|
| Pricing date: | Jan. 13
|
| Settlement date: | Jan. 19
|
| Stock symbol: | Nasdaq: ROSG
|
| Stock price: | $3.09 at close Jan. 6
|
| Market capitalization: | $43.8 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
